SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.
With more than 4.5 million deaths and over 218 million cases1 of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals.
cobas® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.
- Screen asymptomatic individuals in 20 minutes to help prevent the silent spread of SARS-CoV-2
- Mobilize fast testing at your priority points of care for greater access for patients
- Broad strain coverage of SARS-CoV-2 variants for further reassurance with care decisions
The cobas® SARS-CoV-2 assay runs on the cobas® Liat® System. A growing menu of molecular POC assays, together with this innovative analyzer, and the connectivity of cobas® infinity POC solution, forms the Roche total point-of-care PCR solution. Now, emergency rooms, primary care and other novel POC settings can reliably standardize and mobilize molecular testing, enhancing patient safety and satisfaction.